We were shocked — shocked — to learn that 23andMe is cashing in on its customers’ spit. $3.5 billion, the company is worth, they say, now that it’s going public. That is an awful lot of $99 gene tests! Except that the business model is not, and never has been, about cash flow from individual customers. No, the big money is in leasing out genetic data to pharmaceutical companies and other researchers.
"Black-footed Ferret Kits" by USFWS Mountain Prairie
is licensed under CC BY 2.0
The New York Times published on February 18 an enthusiastic article about a black-footed ferret, hailing it as “the first of any native, endangered animal species in North America to be cloned.”
In computer science, the main outlets for peer-reviewed research are not journals but conferences, where accepted papers are presented in the form of talks or posters. In June, 2019, at a large artificial-intelligence conference in Long Beach, California, called Computer...
Bluebird Bio said Tuesday that it has suspended clinical trials involving its gene therapy for sickle cell disease after receiving reports that two patients treated with the one-time therapy were diagnosed with cancer.
The trials were placed on “temporary suspension”...